No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ADVM240719C8000
- 0.50
- -1.00-66.67%
15min DelayClose Jul 17 16:00 ET
1.11High0.35Low
0.35Open1.50Pre Close578 Volume13 Open Interest8.00Strike Price29.18KTurnover329.56%IV-3.19%PremiumJul 19, 2024Expiry Date0.78Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.6865Delta0.1532Gamma6.63Leverage Ratio-0.1973Theta0.0003Rho4.55Eff Leverage0.0025Vega
Intraday
- 5D
- Daily
News
Adverum Biotechnologies' Promising AMD Treatment Advances
Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study
Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD).The 26-week interim analysis was
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for
Adverum Biotechnologies Shares Rise As Eye Disease Treatment Study Advances
By Michael Susin Adverum Biotechnologies shares were higher early Wednesday after the company said that its therapy for wet age-related macular degeneration was selected for a late-stage study.
Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug
Adverum Biotechnologies (ADVM) said Wednesday that a 26-week interim analysis of its mid-stage trial of its novel gene therapy candidate, Ixo-vec, in patients with wet age-related macular
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave.Bloom Energy said it entered into a
Comments
$Adverum Biotechnologies(ADVM.US$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
2
$Adverum Biotechnologies(ADVM.US$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
$Adverum Biotechnologies(ADVM.US$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
Let’s see.
$Adverum Biotechnologies(ADVM.US$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
Read more